APA (7th ed.) Citation

Brownlee, W. J. (2020). COVID-19 and high-efficacy multiple sclerosis therapies: Time for business as usual? Multiple sclerosis, 26(10), 1267. https://doi.org/10.1177/1352458520948211

Chicago Style (17th ed.) Citation

Brownlee, Wallace J. "COVID-19 and High-efficacy Multiple Sclerosis Therapies: Time for Business as Usual?" Multiple Sclerosis 26, no. 10 (2020): 1267. https://doi.org/10.1177/1352458520948211.

MLA (9th ed.) Citation

Brownlee, Wallace J. "COVID-19 and High-efficacy Multiple Sclerosis Therapies: Time for Business as Usual?" Multiple Sclerosis, vol. 26, no. 10, 2020, p. 1267, https://doi.org/10.1177/1352458520948211.